Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
66.57
-2.64 (-3.81%)
Streaming Delayed Price
Updated: 12:32 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
↗
November 02, 2023
NASDAQ:HALO, a growth stock which is not overvalued.
Via
Chartmill
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
↗
October 27, 2023
Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals.
↗
October 24, 2023
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
↗
October 19, 2023
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...
Via
Benzinga
NASDAQ:HALO is showing decent growth, but is still valued reasonably.
↗
October 12, 2023
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via
Chartmill
Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase.
↗
October 11, 2023
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.
Via
Chartmill
Analyst Expectations for Halozyme Therapeutics's Future
↗
October 09, 2023
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
October 06, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via
Chartmill
Where Halozyme Therapeutics Stands With Analysts
↗
September 08, 2023
Via
Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
↗
September 26, 2023
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
↗
September 26, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably.
Via
Chartmill
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
↗
September 23, 2023
Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment.
Via
InvestorPlace
Expert Ratings for Halozyme Therapeutics
↗
August 15, 2023
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
↗
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
Halozyme Therapeutics: Q1 Earnings Insights
↗
May 09, 2023
Via
Benzinga
Halozyme Therapeutics Earnings Preview
↗
May 08, 2023
Via
Benzinga
The Latest Analyst Ratings for Halozyme Therapeutics
↗
March 16, 2023
Via
Benzinga
5 Analysts Have This to Say About Halozyme Therapeutics
↗
February 22, 2023
Via
Benzinga
Halozyme Therapeutics's Earnings: A Preview
↗
February 20, 2023
Via
Benzinga
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
↗
July 24, 2023
HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
↗
July 24, 2023
Via
Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
↗
July 13, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
↗
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 20, 2023
Via
Benzinga
AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs
↗
May 31, 2023
The surge of artificial intelligence (AI) is sparking a transformative shift in the relative valuations of prominent U.S. stock averages as the tech sector outperforms other industries and small-cap...
Via
Benzinga
7 Meme Stocks to Buy Before They Soar to New Heights in 2023
↗
May 25, 2023
Investing in meme stocks is no longer about driving dying companies higher. In fact, let’s get into meme-worthy and investment-grade shares.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
↗
May 10, 2023
Via
Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
↗
March 16, 2023
It's still unclear whether CMS will include those drugs in its negotiation list.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
↗
March 16, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
May 08, 2023
On Monday, 61 companies hit new 52-week lows.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
